Theresa Matkovits

Theresa Matkovits

Director/Board Member at APPILI THERAPEUTICS INC.

Net worth: - $ as of 31/05/2026

58 year
Health Technology
Consumer Services
Distribution Services

Profile

Theresa Matkovits currently works at GoodCap Pharmaceuticals, Inc., as Chairman from 2022 and Appili Therapeutics, Inc., as Lead Independent Director from 2018.
Dr. Matkovits also formerly worked at Aradigm Corp., as Director from 2018 to 2019, BioSurplus, Inc., as Director, Hepion Pharmaceuticals, Inc., as Chief Operating Officer from 2017 to 2018, Novartis AG, as Head-Strategic Planning & Operations from 1997 to 2010, The Medicines Co., as Vice President from 2010 to 2013, and Matinas BioPharma Holdings, Inc., as Chief Development Officer from 2018 to 2024.
Dr. Matkovits received her doctorate degree in 1994 from the University of Medicine & Dentistry of New Jersey and undergraduate degree from Alfred University.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
30/06/2025 0 ( -.--% ) - $ 31/05/2026

Theresa Matkovits active positions

CompaniesPositionStart
APPILI THERAPEUTICS INC. Director/Board Member 01/10/2018
Chairman 01/01/2022

Former positions of Theresa Matkovits

CompaniesPositionEnd
MATINAS BIOPHARMA HOLDINGS, INC. Corporate Officer/Principal 23/10/2024
ARADIGM CORPORATION Director/Board Member 01/02/2019
HEPION PHARMACEUTICALS, INC. Chief Operating Officer 01/10/2018
THE MEDICINES COMPANY Corporate Officer/Principal 01/05/2013
NOVARTIS AG Corporate Officer/Principal 01/01/2010
See the detail of Theresa Matkovits's experience

Training of Theresa Matkovits

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

75

1st degree connections

10

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies10

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Consumer Services

Consumer Services

Distribution Services

Health Technology

Health Technology

  1. Stock Market
  2. Insiders
  3. Theresa Matkovits